These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1892365)

  • 21. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Hoey M; Kutt H; McDowell FH
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
    Djaldetti R; Melamed E
    Ann Neurol; 1996 Mar; 39(3):400-4. PubMed ID: 8602763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
    Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
    Okereke CS
    J Pharm Pharm Sci; 2002; 5(2):146-61. PubMed ID: 12207867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.
    Sage JI; Schuh L; Heikkila RE; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):36-44. PubMed ID: 3349496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complications and limitations of drug therapy for Parkinson's disease.
    Jankovic J
    Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.
    Arabia G; Zappia M; Bosco D; Crescibene L; Bagalà A; Bastone L; Caracciolo M; Scornaienghi M; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S53-4. PubMed ID: 12548340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of slowed gastrointestinal motility on levodopa pharmacokinetics.
    Fernández N; García JJ; Diez MJ; Sahagún AM; González A; Díez R; Sierra M
    Auton Neurosci; 2010 Aug; 156(1-2):67-72. PubMed ID: 20434962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Levodopa loading test as an early marker of Parkinson's disease].
    Hatori K; Kondo T; Mizuno Y
    Nihon Rinsho; 1997 Jan; 55(1):207-12. PubMed ID: 9014451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluctuating levodopa concentrations and Parkinson's disease.
    Juncos J; Serrati C; Fabbrini G; Chase TN
    Lancet; 1985 Aug; 2(8452):440. PubMed ID: 2863459
    [No Abstract]   [Full Text] [Related]  

  • 39. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
    Pierantozzi M; Pietroiusti A; Galante A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Stanzione P
    Ann Neurol; 2001 Nov; 50(5):686-7. PubMed ID: 11706979
    [No Abstract]   [Full Text] [Related]  

  • 40. Contralateral levodopa-induced hemichorea in a patient with severe asymmetric Parkinson's disease.
    Yoo SW; Kim JS
    Acta Neurol Belg; 2020 Jun; 120(3):691-693. PubMed ID: 30840221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.